Monthly Archives: September 2023

Blood donations remain low since COVID while need is constant

The need for blood donations remains constant as nonprofit organizations like Vitalant face many hurdles from before and during the pandemic. While a large percentage of the population is eligible to donate, only a small fraction give blood as many remain afraid to go through the process.  “It saves lives. I mean people that need […]

Angiostrongylus cantonensis Infection in Brown Rats (Rattus norvegicus), Atlanta, Georgia, USA, 2019–2022

Author affiliations: University of Georgia College of Veterinary Medicine, Athens, Georgia, USA (N.L. Gottdenker, B. McHale, B.M. Miller, E.W. Howerth, C.E. Burrell, R. McManamon); Texas A&M University School of Veterinary Medicine and Biomedical Sciences, College Station, Texas, USA (R.A.N. Ramos, H. Hakimi, G.G. Verocai); Zoo Atlanta, Atlanta, Georgia, USA (S. Rivera); Mississippi State University College […]

‘Cyberpunk 2077: Phantom Liberty’ Review: Blood And Sublime

There’s little need to rehash the full, mangled history of Cyberpunk 2077 at this point. It had such a fractured, unpolished launch that it has now become an industry cautionary tale as no one wants to “be another Cyberpunk” at release. CDPR did not want to lose its formerly sterling reputation, so it spent almost […]

Genetically modifying individual cells in animals

With the new method, the cells in individual organs of animals can be genetically modified in a mosaic-like manner (symbol image generated with Midjourney). Credit: ETH Zurich One proven method for tracking down the genetic causes of diseases is to knock out a single gene in animals and study the consequences this has for the […]

Erdafitinib’s ‘Time to Shine’ in FGFR-Altered Urothelial Cancer

Arlene O. Siefker-Radtke, MD According to Arlene O. Siefker-Radtke, MD, erdafitinib (Balversa) represents a potentially groundbreaking advancement for the treatment of metastatic urothelial carcinoma (mUC). Erdafitinib is an FGFR1-4 inhibitor being evaluated for the treatment of patients with urothelial cancer. As a pan-FGFR inhibitor, erdafitinib marks the first biomarker targeted therapy for patients with mUC. […]

The better genetic test for newborns

Researchers suggested in a recent study that broad genetic testing could help safe millions of other children. The results of clinical trial were published recently in the Journal of the American Medical Association. Data showed testing sick newborns full genetic blueprint is nearly twice as good at finding genetic problems or abnormalities compared to narrower, more […]

Australian biobank aims to discover new treatments for children with genetic muscle diseases

An Australian-first biobank will be established to improve and discover new treatments for children with genetic muscle diseases. The National Muscle Disease Bio-databank, co-led by Murdoch Children’s Research Institute, Monash University and Alfred Health, will advance research into understanding why children develop genetic muscle diseases. The project forms part of a $2.5 million Medical Research […]

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

Elcin Barker Ergun The European Commission has approved elacestrant (Orserdu) for the treatment of postmenopausal women and men with estrogen receptor (ER)–positive, HER2-negative, locally advanced, or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least 1 line of endocrine therapy including a CDK4/6 inhibitor.1 The approval was based on […]